CatalYm GmbH

The pioneer for GDF-15
targeting in immuno-oncology

CatalYm has identified GDF-15 as a key regulator of the immune system in the tumor microenvironment. We are pioneering the reversal of GDF-15-mediated immunosuppression to induce a potent antitumoral immune reaction in nonresponsive tumors.

CatalYm’s lead program, CTL-002, is poised to demonstrate clinical proof-of-concept in multiple solid tumor indications and has the potential to expand the treatment horizon for current and future immunotherapies.